Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 19, 2022

SELL
$36.28 - $75.29 $204,038 - $423,430
-5,624 Closed
0 $0
Q1 2022

Apr 20, 2022

BUY
$69.73 - $142.9 $146,014 - $299,232
2,094 Added 59.32%
5,624 $417,000
Q4 2021

Feb 10, 2022

BUY
$134.56 - $217.97 $181,386 - $293,823
1,348 Added 61.78%
3,530 $509,000
Q3 2021

Oct 14, 2021

BUY
$177.8 - $270.58 $38,049 - $57,904
214 Added 10.87%
2,182 $453,000
Q2 2021

Jul 27, 2021

BUY
$121.0 - $257.67 $12,463 - $26,540
103 Added 5.52%
1,968 $416,000
Q1 2021

Apr 20, 2021

SELL
$112.98 - $319.93 $198,279 - $561,477
-1,755 Reduced 48.48%
1,865 $338,000
Q4 2020

Jan 29, 2021

SELL
$78.74 - $139.5 $1,811 - $3,208
-23 Reduced 0.63%
3,620 $404,000
Q3 2020

Oct 21, 2020

BUY
$79.44 - $178.51 $289,399 - $650,311
3,643 New
3,643 $394,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $722M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Great Valley Advisor Group, Inc. Portfolio

Follow Great Valley Advisor Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Valley Advisor Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Great Valley Advisor Group, Inc. with notifications on news.